Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"

From blackwiki
Jump to navigation Jump to search
imported>Qwfp
(wikilink author)
(Remove inline styling from table: Prone to not displaying well on low width resolution displays, especially with margins.)
Line 1: Line 1:
{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="width:700px; text-align:left; margin-left:auto; margin-right:auto; border:none;"
+
{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
 
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
 
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
 
|-
 
|-

Revision as of 08:37, 27 March 2019

Health risks in the CEEs/MPA substudy of the Women's Health Initiative

Event Relative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI*) Placebo
(n = 8102)
CEEs/MPA
(n = 8506)
Absolute Risk per 10,000 Women-Years
Coronary heart disease events
  Non-fatal myocardial infarction
  Coronary heart disease death
1.29 (1.02–1.63)
1.32 (1.02–1.72)
1.18 (0.70–1.97)
30
23
6
37
30
7
Invasive breast cancera 1.26 (1.00–1.59) 30 38
Stroke 1.41 (1.07–1.85) 21 29
Pulmonary embolism 2.13 (1.39–3.25) 8 16
Colorectal cancer 0.63 (0.43–0.92) 16 10
Endometrial cancer 0.83 (0.47–1.47) 6 5
Hip fracture 0.66 (0.45–0.98) 15 10
Death due to causes other than above 0.92 (0.74–1.14) 40 37
Global Indexb 1.15 (1.03–1.28) 151 170
Deep vein thrombosisc 2.07 (1.49–2.87) 13 26
Vertebral fracturesc 0.66 (0.44–0.98) 15 9
Other osteoporotic fracturesc 0.77 (0.69–0.86) 170 131
Abbreviations: WHI = Template:No selflink. CEEs = Template:No selflink. MPA = Template:No selflink. Notes: Dosages were 0.625 mg/day CEEs and 2.5 mg/day MPA. Footnotes: a = Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. b = A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. c = Not included in Global Index. * = Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. Sources: [1][2]

References

  1. Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
  2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.